SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Horizon Therapeutics Public Limited Company (HZNP) trades at a trailing P/E of 52.4. Trailing earnings yield is 1.91%.
Criteria proven by this page:
- VALUE (40/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Trailing Earnings Yield 1.91% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
- Analyst consensus target $127.15 (+9.3% upside) — modest upside expected.
Overall SharesGrow Score: 68/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
40/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HZNP
Valuation Multiples
P/E (TTM)52.4
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio7.54
EV/EBITDA0.0
Per Share Data
EPS (TTM)$2.22
Book Value / Share$0.00
Revenue / Share$15.43
FCF / Share$0.00
Yields & Fair Value
Earnings Yield1.91%
Dividend Yield0.00%
Analyst Target$127.15 (+9.3%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-2.34 |
$74.02M |
$-149.01M |
-201.3% |
| 2014 |
$-3.15 |
$296.96M |
$-263.6M |
-88.8% |
| 2015 |
$0.25 |
$757.04M |
$39.53M |
5.2% |
| 2016 |
$-1.04 |
$981.12M |
$-166.83M |
-17% |
| 2017 |
$-2.52 |
$1.06B |
$-410.53M |
-38.9% |
| 2018 |
$-0.45 |
$1.21B |
$-74.19M |
-6.1% |
| 2019 |
$2.90 |
$1.3B |
$573.02M |
44.1% |
| 2020 |
$1.81 |
$2.2B |
$389.8M |
17.7% |
| 2021 |
$2.27 |
$3.23B |
$534.49M |
16.6% |
| 2022 |
$2.22 |
$3.63B |
$521.48M |
14.4% |
